Present and future DNA vaccines for chronic hepatitis B treatment

References

• Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008 Oct 2;359(14):1486–1500.
   PubMed Web of Science ®Google Scholar
• Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimation of worldwide prevalence of chronic hepatitis B virus infection: a systemic review of data published between 1965 and 2013. Lancet. 2015 Oct 17;386(10003):1546–1555.
   PubMed Web of Science ®Google Scholar
• Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat. 2012 Jun;19(6):377–386. DOI:10.1111/j.1365-2893.2012.01602.x
   PubMed Web of Science ®Google Scholar
• Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther. 2010;15(Suppl 3):3–14. DOI:10.3851/IMP1619
   PubMed Web of Science ®Google Scholar
• Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016 Apr;64(1 Suppl):S117–S131. DOI:10.1016/j.jhep.2016.02.016
   PubMed Web of Science ®Google Scholar
• Zoulim F. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res. 2012 Nov;96(2):256–259. DOI:10.1016/j.antiviral.2012.09.006
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012 Dec;61(12):1754–1764. DOI:10.1136/gutjnl-2011-301073
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005 Mar;5(3):215–229. DOI:10.1038/nri1573
   PubMed Web of Science ®Google Scholar
• Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010 Aug;58(4):258–266. DOI:10.1016/j.patbio.2009.11.001
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016 Apr;64(1 Suppl):S71–S83. DOI:10.1016/j.jhep.2016.01.026
   PubMedGoogle Scholar
• Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010 Feb;138(2):682–693. DOI:10.1053/j.gastro.2009.09.052
   PubMed Web of Science ®Google Scholar
• Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005 Aug;79(15):9369–9380. DOI:10.1128/JVI.79.15.9369-9380.2005
   PubMed Web of Science ®Google Scholar
• Lucifora J, Durantel D, Testoni B, et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology. 2010 Jan;51(1):63–72. DOI:10.1002/hep.23230
   PubMed Web of Science ®Google Scholar
• Lütgehetmann M, Bornscheuer T, Volz T, et al. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology. 2011 Jun;140(7):2074–2083. DOI:10.1053/j.gastro.2011.02.057
   PubMed Web of Science ®Google Scholar
• Luangsay S, Gruffaz M, Isorce N, et al. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015 Dec;63(6):1314–1322. DOI:10.1016/j.jhep.2015.07.014
   PubMed Web of Science ®Google Scholar
• Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol. 2016 Apr;64(1 Suppl):S60–S70. DOI:10.1016/j.jhep.2016.01.028
   PubMedGoogle Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. 2005 Jul 15;175(2):633–639.
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Talbott KT, Choo DK, et al. Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines. 2013 May;12(5):537–554. DOI:10.1586/erv.13.33
   PubMed Web of Science ®Google Scholar
• Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012 Feb;11(2):189–209. DOI:10.1586/erv.11.188
   PubMed Web of Science ®Google Scholar
• Michel M-L, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011 Jun;54(6):1286–1296. DOI:10.1016/j.jhep.2010.12.031
   PubMed Web of Science ®Google Scholar
• Cova L. Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. Curr Gene Ther. 2014;14(3):149–160.
   PubMed Web of Science ®Google Scholar
• Mancini M, Hadchouel M, Davis HL, et al. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12496–12501.
   PubMed Web of Science ®Google Scholar
• Mancini M, Hadchouel M, Tiollais P, et al. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. J Immunol. 1998 Nov 15;161(10):5564–5570.
   PubMed Web of Science ®Google Scholar
• Obeng-Adjei N, Choo DK, Saini J, et al. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. Cancer Gene Ther. 2012 Nov;19(11):779–787. DOI:10.1038/cgt.2012.61
   PubMed Web of Science ®Google Scholar
• Zoulim F, Saade F, Buronfosse T, et al. Animal models for the study of infection. In: Lai CL, Locarnini S, editors. Hepatitis B virus. London: International Medical Press; 2008. p. 6.1–6.20.
   Google Scholar
• Cova L, Zoulim F. Duck hepatitis B virus model in the study of hepatitis B virus. Methods Mol Med. 2004;96:261–268. DOI:10.1385/1-59259-670-3:261
   PubMedGoogle Scholar
• Kosinska AD, Zhang E, Lu M, et al. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat. 2010;2010:817580.
   PubMedGoogle Scholar
• Rollier C, Sunyach C, Barraud L, et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology. 1999 Mar;116(3):658–665.
   PubMed Web of Science ®Google Scholar
• Foster WK, Miller DS, Marion PL, et al. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother. 2003 Aug;47(8):2624–2635.
   PubMed Web of Science ®Google Scholar
• Thermet A, Buronfosse T, Werle-Lapostolle B, et al. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol. 2008 May;89(Pt 5):1192–1201. DOI:10.1099/vir.0.83583-0
   PubMed Web of Science ®Google Scholar
• Kosinska AD, Zhang E, Johrden L, et al. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. Plos Pathog. 2013 Jun;9(6):e1003391. DOI:10.1371/journal.ppat.1003391
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. Plos Pathog. 2014 Jan;10(1):e1003856. DOI:10.1371/journal.ppat.1003856
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 2001 Apr;33(4):963–971. DOI:10.1053/jhep.2001.23045
   PubMed Web of Science ®Google Scholar
• Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol. 1998 Feb 1;160(3):1320–1329.
   PubMed Web of Science ®Google Scholar
• Siegel F, Lu M, Roggendorf M. Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection. J Virol. 2001 Jun;75(11):5036–5042. DOI:10.1128/JVI.75.11.5036-5042.2001
   PubMed Web of Science ®Google Scholar
• Wang J, Gujar SA, Cova L, et al. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol. 2007 Jan;81(2):903–916. DOI:10.1128/JVI.01537-06
   PubMed Web of Science ®Google Scholar
• Saade F, Buronfosse T, Pradat P, et al. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes. Vaccine. 2008 Sep 19;26(40):5159–5164.
   PubMed Web of Science ®Google Scholar
• Saade F, Buronfosse T, Guerret S, et al. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes. J Viral Hepat. 2013 Apr;20(4):e56–e65. DOI:10.1111/jvh.12023
   Google Scholar
• Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther. 2007 Nov;7(11):1647–1664. DOI:10.1517/14712598.7.11.1647
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011 Jun;23(3):421–429. DOI:10.1016/j.coi.2011.03.008
   PubMed Web of Science ®Google Scholar
• Flingai S, Czerwonko M, Goodman J, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013 Nov;4(4):354. DOI:10.3389/fimmu.2013.00354
   PubMed Web of Science ®Google Scholar
• Sällberg M, Frelin L, Ahlén G, et al. Electroporation for therapeutic DNA vaccination in patients. Med Microbiol Immunol. 2015 Feb;204(1):131–135. DOI:10.1007/s00430-014-0384-8
   PubMed Web of Science ®Google Scholar
• Peng J, Shi S, Yang Z, et al. Short noncoding DNA fragments improve the immune potency of electroporation-mediated HBV DNA vaccination. Gene Ther. 2014 Jul;21(7):703–708. DOI:10.1038/gt.2014.44
   PubMed Web of Science ®Google Scholar
• Kim CY, Kang ES, Kim SB, et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med. 2008 Dec 31;40(6):669–676.
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Hannaman D, Ellefsen B, et al. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine. 2006 May 22;24(21):4490–4493.
   PubMed Web of Science ®Google Scholar
• van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines. 2010 May;9(5):503–517. DOI:10.1586/erv.10.42
   PubMed Web of Science ®Google Scholar
• Reed SD, Li S. Electroporation advances in large animals. Curr Gene Ther. 2009 Aug;9(4):316–326.
   PubMed Web of Science ®Google Scholar
• Babiuk S, Baca-Estrada ME, Foldvari M, et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine. 2002;20:9. DOI:10.1016/S0264-410X(02)00269-4
   Web of Science ®Google Scholar
• van Drunen Littel-van den Hurk S, Luxembourg A, Ellefsen B, et al. Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine. 2008 Oct 9;26(43):5503–5509.
   PubMed Web of Science ®Google Scholar
• Liu KH, Ascenzi MA, Bellezza CA, et al. Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks. J Virol. 2011 May;85(10):4853–4862. DOI:10.1128/JVI.02437-10
   PubMed Web of Science ®Google Scholar
• Khawaja G, Buronfosse T, Jamard C, et al. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation. Virology. 2012 Mar 30;425(1):61–69.
   PubMed Web of Science ®Google Scholar
• Brass A, Frelin L, Milich DR, et al. Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination. Mol Ther. 2015 Mar;23(3):578–590. DOI:10.1038/mt.2014.233
   PubMed Web of Science ®Google Scholar
• Khawaja G, Buronfosse T, Jamard C, et al. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. Virology. 2012 Nov 10;433(1):192–202. DOI:10.1016/j.virol.2012.07.014
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Scott-Algara D, et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology. 2004 Oct;40(4):874–884. DOI:10.1002/hep.20408
   PubMed Web of Science ®Google Scholar
• Scott-Algara D, Mancini-Bourgine M, Fontaine H, et al. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. Plos One. 2010;5(1):e8761. DOI:10.1371/journal.pone.0008761
   Google Scholar
• Godon O, Fontaine H, Kahi S, et al. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther. 2014 Mar;22(3):675–684. DOI:10.1038/mt.2013.274
   PubMed Web of Science ®Google Scholar
• Fontaine H, Kahi S, Chazallon C, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut. 2015 Jan;64(1):139–147. DOI:10.1136/gutjnl-2013-305707
   PubMed Web of Science ®Google Scholar
• Yang S-H, Lee C-G, Park S-H, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther. 2006 Jul;13(14):1110–1117. DOI:10.1038/sj.gt.3302751
   PubMed Web of Science ®Google Scholar
• Im SJ, Yang SH, Yoon SK, et al. Increase of plasma IL-12/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers. Immune Netw. 2009 Feb;9(1):20–26. DOI:10.4110/in.2009.9.1.20
   PubMedGoogle Scholar
• Yoon SK, Seo YB, Im SJ, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. 2015 Mar;35(3):805–815. DOI:10.1111/liv.12530
   PubMed Web of Science ®Google Scholar
• Yang F-Q, Yu Y-Y, Wang G-Q, et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat. 2012 Aug;19(8):581–593. DOI:10.1111/j.1365-2893.2012.01589.x
   PubMed Web of Science ®Google Scholar
• Phase I study of INO-1800 with or without INO-9112 + EP in chronic hepatitis B subjects. Inovio Pharmaceuticals. Available from: https://clinicaltrials.gov/ct2/show/NCT02431312
   Google Scholar